» Articles » PMID: 26771870

Buprenorphine Maintenance Treatment of Opiate Dependence: Correlations Between Prescriber Beliefs and Practices

Overview
Publisher Informa Healthcare
Date 2016 Jan 16
PMID 26771870
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite the existence of evidence-based guidelines, different prescriber practices around buprenorphine maintenance treatment (BMT) of opiate dependence exist. Moreover, certain prescriber beliefs may influence their practice patterns.

Objective: To understand community BMT practice patterns and discern their relationship to practitioner beliefs.

Method: Survey of 30 local BMT prescribers about aspects of BMT, and analysis of correlations between practices and practitioner beliefs.

Results: Practitioners generally followed standard treatment guidelines, though the most-common maintenance dosages of BMT (4-12 mg) were lower than recommended by some studies. Endorsement of belief in a "spiritual basis" of addiction correlated with lower average BMT doses and less frequent endorsement of the belief that BMT-treated patients are "in recovery."

Conclusions/importance: These data suggest that relatively standardized, longer-term BMT of opiate dependence is accepted among the majority of surveyed prescribers, and certain provider beliefs about addiction may influence prescribing habits and attitudes. Future studies should: (1) assess these findings in larger samples; (2) examine how prescriber beliefs about addiction and BMT compare with those of other addiction treatment providers; and (3) ascertain whether individual prescriber beliefs influence patient outcomes.

Citing Articles

An interrupted time series analysis of fentanyl, naloxone, and opioid-involved deaths in five counties in Eastern Missouri.

Newman S, McNamara I, Campbell K, Park B, Carpenter R, Blanchard B J Subst Use Addict Treat. 2024; 169:209564.

PMID: 39505112 PMC: 11769757. DOI: 10.1016/j.josat.2024.209564.


The association of medical providers' attitudes about naloxone and people with opioid use disorder and their self-reported "low-barrier" treatment practices.

Winograd R, Coffey B, Nance M, Carpenter R Addict Behav Rep. 2023; 18:100514.

PMID: 37680698 PMC: 10480593. DOI: 10.1016/j.abrep.2023.100514.


Targeting Opioid Receptors in Addiction and Drug Withdrawal: Where Are We Going?.

Tabanelli R, Brogi S, Calderone V Int J Mol Sci. 2023; 24(13).

PMID: 37446064 PMC: 10341731. DOI: 10.3390/ijms241310888.


Impact of Stigma on Clinician Training for Opioid Use Disorder Care: A Qualitative Study in a Primary Care Learning Collaborative.

Klusaritz H, Bilger A, Paterson E, Summers C, Barg F, Cronholm P Ann Fam Med. 2023; 21(Suppl 2):S31-S38.

PMID: 36849482 PMC: 9970664. DOI: 10.1370/afm.2920.


Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives.

Kelley A, Wilcox J, Baylis J, Crossnohere N, Magel J, Jones A J Gen Intern Med. 2022; 38(9):2147-2155.

PMID: 36471194 PMC: 10361924. DOI: 10.1007/s11606-022-07975-7.